CVM Cel Sci Corp

  1. Stocks
  2. Healthcare
  3. NYSEAMERICAN: CVM

Price (delayed)

$2.25

Market cap

$106.34M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.78

Enterprise value

$112.88M

CEL-SCI believes that boosting a patient’s immune system while it is still intact should provide the greatest possible impact on survival. Therefore, in the Phase 3 study CEL-SCI treated patients ...

Highlights
CVM's debt is down by 11% year-on-year and by 3% since the previous quarter
CVM's net income is up by 8% year-on-year and by 4.4% since the previous quarter
Cel Sci's quick ratio has plunged by 80% YoY and by 39% from the previous quarter
The equity has plunged by 62% YoY and by 27% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cel-sci.com/
Peers: CRIS BCRX AMGN TEVA

Key stats

What are the main financial stats of CVM
Market
Shares outstanding
47.26M
Market cap
$106.34M
Enterprise value
$112.88M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.8
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$33.72M
EBITDA
-$29.71M
Free cash flow
-$23.1M
Per share
EPS
-$0.78
Free cash flow per share
-$0.52
Book value per share
$0.33
Revenue per share
$0
TBVPS
$0.73
Balance sheet
Total assets
$32.32M
Total liabilities
$17.53M
Debt
$14.02M
Equity
$14.79M
Working capital
$2.44M
Liquidity
Debt to equity
0.95
Current ratio
1.46
Quick ratio
1.41
Net debt/EBITDA
-0.22
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-81.7%
Return on equity
-144.4%
Return on invested capital
-94.4%
Return on capital employed
-124.8%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CVM stock price

How has the Cel Sci stock price performed over time
Intraday
-8.16%
1 week
-4.26%
1 month
85.95%
1 year
-19.64%
YTD
-4.26%
QTD
80%

Financial performance

How have Cel Sci's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$33.02M
Net income
-$33.83M
Gross margin
N/A
Net margin
N/A
CVM's net income is up by 8% year-on-year and by 4.4% since the previous quarter
Cel Sci's operating income has increased by 7% YoY

Growth

What is Cel Sci's growth rate over time

Valuation

What is Cel Sci stock price valuation
P/E
N/A
P/B
6.8
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 8% YoY and by 4.9% QoQ
The stock's price to book (P/B) is 78% less than its 5-year quarterly average of 34.3 but 45% more than its last 4 quarters average of 5.1
The equity has plunged by 62% YoY and by 27% from the previous quarter

Efficiency

How efficient is Cel Sci business performance
CVM's return on equity has dropped by 89% year-on-year and by 20% since the previous quarter
The return on assets has declined by 48% year-on-year and by 10% since the previous quarter
Cel Sci's return on invested capital has decreased by 18% YoY and by 2.3% QoQ

Dividends

What is CVM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CVM.

Financial health

How did Cel Sci financials performed over time
The total assets is 84% more than the total liabilities
Cel Sci's current ratio has plunged by 81% YoY and by 38% from the previous quarter
Cel Sci's quick ratio has plunged by 80% YoY and by 39% from the previous quarter
CVM's debt is 5% smaller than its equity
The company's debt to equity has surged by 132% YoY and by 32% QoQ
The equity has plunged by 62% YoY and by 27% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.